The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...

Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on ...

Jeanne Shaheen, D-N.H., the ranking Democrat on the Appropriations Committee’s subcommittee on Agriculture, Rural Development ... They underscore that the FDA’s drug, device and tobacco ...

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete ...

Drug development is an expensive and high-risk process. The median cost per approved drug can reach up to $2.8 billion, ...

Sterotherapeutics, a leading biopharmaceutical company dedicated to advancing innovative therapies, is announcing the launch of a Phase 2 clinical trial for ST-002, a novel drug candidate for patients ...

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...

Strong evidence for ALS often comes from familial forms of the disease, where specific gene mutations— for example in the ...

NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable ...

The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, which was accepted by ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through ...

According to the US regulator, the use of AI in drug development and ... engage with it early on in the development process to get feedback on credibility. The FDA action follows the finalisation ...